Review



partial least squares discriminant analysis pls da models  (Umetrics)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Umetrics partial least squares discriminant analysis pls da models
    Multivariate analysis of urinary ¹H NMR metabolomic profiles across groups: Primary Mitochondrial Disease (PMD, orange), Suspected Mitochondrial Disease (SMD, yellow), Control individuals (green), Chronic Kidney Disease (CKD) stages 1–2 (lilac) and stages 3–5 (purple). The ellipses represent 95% confidence intervals. A Principal Component Analysis (PCA) highlights distinct metabolic fingerprint in CKD patients compared to other groups. B Corresponding supervised model using <t>partial</t> <t>least</t> <t>squares</t> discriminant analysis <t>(PLS-DA)</t> shows metabolic divergence between groups, particularly between PMD, CKD3-5, and controls. PMD primary mitochondrial disease, SMD suspected mitochondrial dysfunction, CKD chronic kidney disease
    Partial Least Squares Discriminant Analysis Pls Da Models, supplied by Umetrics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/partial+least-squares+discrimination+analysis+(pls-da)/1+14+simca/pmc12812765-108-9-16
    Average 86 stars, based on 1 article reviews
    partial least squares discriminant analysis pls da models - by Bioz Stars, 2026-10
    86/100 stars

    Images

    1) Product Images from "NMR-based urinary biomarkers in pediatric primary mitochondrial disorders and chronic kidney disease: shared mitochondrial dysfunction, diverging biosignatures"

    Article Title: NMR-based urinary biomarkers in pediatric primary mitochondrial disorders and chronic kidney disease: shared mitochondrial dysfunction, diverging biosignatures

    Journal: Metabolomics

    doi: 10.1007/s11306-025-02363-8

    Multivariate analysis of urinary ¹H NMR metabolomic profiles across groups: Primary Mitochondrial Disease (PMD, orange), Suspected Mitochondrial Disease (SMD, yellow), Control individuals (green), Chronic Kidney Disease (CKD) stages 1–2 (lilac) and stages 3–5 (purple). The ellipses represent 95% confidence intervals. A Principal Component Analysis (PCA) highlights distinct metabolic fingerprint in CKD patients compared to other groups. B Corresponding supervised model using partial least squares discriminant analysis (PLS-DA) shows metabolic divergence between groups, particularly between PMD, CKD3-5, and controls. PMD primary mitochondrial disease, SMD suspected mitochondrial dysfunction, CKD chronic kidney disease
    Figure Legend Snippet: Multivariate analysis of urinary ¹H NMR metabolomic profiles across groups: Primary Mitochondrial Disease (PMD, orange), Suspected Mitochondrial Disease (SMD, yellow), Control individuals (green), Chronic Kidney Disease (CKD) stages 1–2 (lilac) and stages 3–5 (purple). The ellipses represent 95% confidence intervals. A Principal Component Analysis (PCA) highlights distinct metabolic fingerprint in CKD patients compared to other groups. B Corresponding supervised model using partial least squares discriminant analysis (PLS-DA) shows metabolic divergence between groups, particularly between PMD, CKD3-5, and controls. PMD primary mitochondrial disease, SMD suspected mitochondrial dysfunction, CKD chronic kidney disease

    Techniques Used: Metabolomic, Control

    Supervised multivariate models and spectral features associated with mitochondrial disorders. I. Partial Least Squares Discriminant Analysis (PLS-DA) models were generated to compare patients with PMD to: A controls, B SMD, C . CKD stages 1–2, and D . CKD stages 3–5. The corresponding Q² values, indicate the predictive performance of each model. Clear discrimination was observed between PMD and controls (Q² = 0.53), and both CKD subgroups (Q² = 0.62 and 0.78). In contrast, the model comparing PMD to SMD showed lower predictive performance (Q² = 0.25), reflecting significant metabolic overlap. II. Corresponding loadings plot of model A, color-coded by variable importance in projection (VIP) scores for the first latent variable (LV1) highlighting spectral regions that contribute most to the separation between PMD and controls. (regions around 1.2–2.5 ppm and 3.0–4.5 ppm, consistent with metabolites involved in amino acid metabolism, organic acids, and energy-related pathways). Three-letter code used for amino acids. Abbreviations: 3-HBA: 3-hydroxybutyrate; 4-HPA: 4-hydroxyphenylacetate; N -PhAcGly: N -phenylacetylglycine. Ui: resonances at chemical shift i, which remain unassigned (or with tentative assignment)
    Figure Legend Snippet: Supervised multivariate models and spectral features associated with mitochondrial disorders. I. Partial Least Squares Discriminant Analysis (PLS-DA) models were generated to compare patients with PMD to: A controls, B SMD, C . CKD stages 1–2, and D . CKD stages 3–5. The corresponding Q² values, indicate the predictive performance of each model. Clear discrimination was observed between PMD and controls (Q² = 0.53), and both CKD subgroups (Q² = 0.62 and 0.78). In contrast, the model comparing PMD to SMD showed lower predictive performance (Q² = 0.25), reflecting significant metabolic overlap. II. Corresponding loadings plot of model A, color-coded by variable importance in projection (VIP) scores for the first latent variable (LV1) highlighting spectral regions that contribute most to the separation between PMD and controls. (regions around 1.2–2.5 ppm and 3.0–4.5 ppm, consistent with metabolites involved in amino acid metabolism, organic acids, and energy-related pathways). Three-letter code used for amino acids. Abbreviations: 3-HBA: 3-hydroxybutyrate; 4-HPA: 4-hydroxyphenylacetate; N -PhAcGly: N -phenylacetylglycine. Ui: resonances at chemical shift i, which remain unassigned (or with tentative assignment)

    Techniques Used: Generated

    Related Articles

    other:

    Article Title: Metabolomics strategy assisted by transcriptomics analysis to identify biomarkers associated with schizophrenia.
    Article Snippet: Metabolomics strategy was applied to select the novel biomarkers associated with schizophrenia under the aid of transcriptomics analysis. a-CEHC, neuraminic acid, glyceraldehyde and asparagine were identified and used to establish the diagnostic panel.. The diagnostic model had better performance in distinguishing schizophrenia patients from healthy people than traditional method (WHO-DAS score). a r t i c l e i n f o

    Article Title: Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis
    Article Snippet: Partial least squares-discrimination analysis (PLS-DA) and orthagonal partial least squares-discrimination analysis (OPLS-DA) were performed using MetaboAnalyst v4.0 or SIMCA v14.1 software (Umetrics, Umea, Sweden) after mean centring and unit variance scaling of lipid mediator concentrations.

    Article Title: Identifying the Novel Gut Microbial Metabolite Contributing to Metabolic Syndrome in Children Based on Integrative Analyses of Microbiome-Metabolome Signatures.
    Article Snippet: A supervised model of partial least-squares discrimination analysis (PLS-DA) was applied to assess the metabolic alterations among groups in Simca-P V.14.0 (Umetrics AB) (62).

    Article Title: PD n-3 DPA Pathway Regulates Human Monocyte Differentiation and Macrophage Function
    Article Snippet: Partial least squares-discrimination analysis (PLS-DA) and principal component analysis (PCA) (Janes and Yaffe, 2006) were performed using SIMCA 14.1 software (Umetrics, Umea, Sweden) following mean centering and unit variance scaling of LM levels.

    Article Title: Qing-Luo-Yin Alleviated Experimental Arthritis in Rats by Disrupting Immune Feedback Between Inflammatory T Cells and Monocytes: Key Evidences from Its Effects on Immune Cell Phenotypes
    Article Snippet: Partial least squares-discrimination analysis (PLS-DA) and corresponding seven-fold cross-validation were performed using SIMCA v.14.1 (Umetrics, Umeå, Sweden).

    Article Title: Triacylglycerols in human milk and their association with edible oils in maternal diet: A study of five regions in China
    Article Snippet: Triacylglycerol (TAG) is the predominant lipid in human milk fat (~98 %).. The association between TAG and maternal diet is interesting but barely understood.. In this study, we analyzed the TAG composition in human milk of mothers consuming seven edible oils during three lactation stages in five cities in China.

    Article Title: Identifying the Novel Gut Microbial Metabolite Contributing to Metabolic Syndrome in Children Based on Integrative Analyses of Microbiome-Metabolome Signatures
    Article Snippet: A supervised model of partial least-squares discrimination analysis (PLS-DA) was applied to assess the metabolic alterations among groups in Simca-P V.14.0 (Umetrics AB) ( ).



    Similar Products

    86
    Umetrics partial least squares discriminant analysis pls da models
    Multivariate analysis of urinary ¹H NMR metabolomic profiles across groups: Primary Mitochondrial Disease (PMD, orange), Suspected Mitochondrial Disease (SMD, yellow), Control individuals (green), Chronic Kidney Disease (CKD) stages 1–2 (lilac) and stages 3–5 (purple). The ellipses represent 95% confidence intervals. A Principal Component Analysis (PCA) highlights distinct metabolic fingerprint in CKD patients compared to other groups. B Corresponding supervised model using <t>partial</t> <t>least</t> <t>squares</t> discriminant analysis <t>(PLS-DA)</t> shows metabolic divergence between groups, particularly between PMD, CKD3-5, and controls. PMD primary mitochondrial disease, SMD suspected mitochondrial dysfunction, CKD chronic kidney disease
    Partial Least Squares Discriminant Analysis Pls Da Models, supplied by Umetrics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/partial+least-squares+discrimination+analysis+(pls-da)/1+14+simca/pmc12812765-108-9-16
    Average 86 stars, based on 1 article reviews
    partial least squares discriminant analysis pls da models - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    90
    Metax GmbH partial least squares discriminant analysis (pls-da) software
    Multivariate analysis of urinary ¹H NMR metabolomic profiles across groups: Primary Mitochondrial Disease (PMD, orange), Suspected Mitochondrial Disease (SMD, yellow), Control individuals (green), Chronic Kidney Disease (CKD) stages 1–2 (lilac) and stages 3–5 (purple). The ellipses represent 95% confidence intervals. A Principal Component Analysis (PCA) highlights distinct metabolic fingerprint in CKD patients compared to other groups. B Corresponding supervised model using <t>partial</t> <t>least</t> <t>squares</t> discriminant analysis <t>(PLS-DA)</t> shows metabolic divergence between groups, particularly between PMD, CKD3-5, and controls. PMD primary mitochondrial disease, SMD suspected mitochondrial dysfunction, CKD chronic kidney disease
    Partial Least Squares Discriminant Analysis (Pls Da) Software, supplied by Metax GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/partial+least-squares+discrimination+analysis+(pls-da)/partial+least+squares+discriminant+analysis++pls+da++software/pmc12189806-93-31-36
    Average 90 stars, based on 1 article reviews
    partial least squares discriminant analysis (pls-da) software - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    MathWorks Inc partial least-squares discrimination analysis (pls-da) classification method
    Multivariate analysis of urinary ¹H NMR metabolomic profiles across groups: Primary Mitochondrial Disease (PMD, orange), Suspected Mitochondrial Disease (SMD, yellow), Control individuals (green), Chronic Kidney Disease (CKD) stages 1–2 (lilac) and stages 3–5 (purple). The ellipses represent 95% confidence intervals. A Principal Component Analysis (PCA) highlights distinct metabolic fingerprint in CKD patients compared to other groups. B Corresponding supervised model using <t>partial</t> <t>least</t> <t>squares</t> discriminant analysis <t>(PLS-DA)</t> shows metabolic divergence between groups, particularly between PMD, CKD3-5, and controls. PMD primary mitochondrial disease, SMD suspected mitochondrial dysfunction, CKD chronic kidney disease
    Partial Least Squares Discrimination Analysis (Pls Da) Classification Method, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/partial+least-squares+discrimination+analysis+(pls-da)/pmc12199223-122-2-20
    Average 90 stars, based on 1 article reviews
    partial least-squares discrimination analysis (pls-da) classification method - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    Umetrics partial-least-squares discriminant analysis (pls-da)
    Multivariate analysis of urinary ¹H NMR metabolomic profiles across groups: Primary Mitochondrial Disease (PMD, orange), Suspected Mitochondrial Disease (SMD, yellow), Control individuals (green), Chronic Kidney Disease (CKD) stages 1–2 (lilac) and stages 3–5 (purple). The ellipses represent 95% confidence intervals. A Principal Component Analysis (PCA) highlights distinct metabolic fingerprint in CKD patients compared to other groups. B Corresponding supervised model using <t>partial</t> <t>least</t> <t>squares</t> discriminant analysis <t>(PLS-DA)</t> shows metabolic divergence between groups, particularly between PMD, CKD3-5, and controls. PMD primary mitochondrial disease, SMD suspected mitochondrial dysfunction, CKD chronic kidney disease
    Partial Least Squares Discriminant Analysis (Pls Da), supplied by Umetrics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/partial+least-squares+discrimination+analysis+(pls-da)/simca+13/pm40483499-88-9-15
    Average 90 stars, based on 1 article reviews
    partial-least-squares discriminant analysis (pls-da) - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    Umetrics partial least squares discriminant analysis (pls-da) models
    Multivariate analysis of urinary ¹H NMR metabolomic profiles across groups: Primary Mitochondrial Disease (PMD, orange), Suspected Mitochondrial Disease (SMD, yellow), Control individuals (green), Chronic Kidney Disease (CKD) stages 1–2 (lilac) and stages 3–5 (purple). The ellipses represent 95% confidence intervals. A Principal Component Analysis (PCA) highlights distinct metabolic fingerprint in CKD patients compared to other groups. B Corresponding supervised model using <t>partial</t> <t>least</t> <t>squares</t> discriminant analysis <t>(PLS-DA)</t> shows metabolic divergence between groups, particularly between PMD, CKD3-5, and controls. PMD primary mitochondrial disease, SMD suspected mitochondrial dysfunction, CKD chronic kidney disease
    Partial Least Squares Discriminant Analysis (Pls Da) Models, supplied by Umetrics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/partial+least-squares+discrimination+analysis+(pls-da)/simca+13/pm40431435-71-14-20
    Average 90 stars, based on 1 article reviews
    partial least squares discriminant analysis (pls-da) models - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    Metax GmbH partial least squares discriminant analysis (pls-da)
    Multivariate analysis of urinary ¹H NMR metabolomic profiles across groups: Primary Mitochondrial Disease (PMD, orange), Suspected Mitochondrial Disease (SMD, yellow), Control individuals (green), Chronic Kidney Disease (CKD) stages 1–2 (lilac) and stages 3–5 (purple). The ellipses represent 95% confidence intervals. A Principal Component Analysis (PCA) highlights distinct metabolic fingerprint in CKD patients compared to other groups. B Corresponding supervised model using <t>partial</t> <t>least</t> <t>squares</t> discriminant analysis <t>(PLS-DA)</t> shows metabolic divergence between groups, particularly between PMD, CKD3-5, and controls. PMD primary mitochondrial disease, SMD suspected mitochondrial dysfunction, CKD chronic kidney disease
    Partial Least Squares Discriminant Analysis (Pls Da), supplied by Metax GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/partial+least-squares+discrimination+analysis+(pls-da)/partial+least+squares+discriminant+analysis++pls+da++software/pm40239901-134-3-10
    Average 90 stars, based on 1 article reviews
    partial least squares discriminant analysis (pls-da) - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    BGI Genomics Co partial least squares discriminant analysis (pls-da)
    Multivariate analysis of urinary ¹H NMR metabolomic profiles across groups: Primary Mitochondrial Disease (PMD, orange), Suspected Mitochondrial Disease (SMD, yellow), Control individuals (green), Chronic Kidney Disease (CKD) stages 1–2 (lilac) and stages 3–5 (purple). The ellipses represent 95% confidence intervals. A Principal Component Analysis (PCA) highlights distinct metabolic fingerprint in CKD patients compared to other groups. B Corresponding supervised model using <t>partial</t> <t>least</t> <t>squares</t> discriminant analysis <t>(PLS-DA)</t> shows metabolic divergence between groups, particularly between PMD, CKD3-5, and controls. PMD primary mitochondrial disease, SMD suspected mitochondrial dysfunction, CKD chronic kidney disease
    Partial Least Squares Discriminant Analysis (Pls Da), supplied by BGI Genomics Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/partial+least-squares+discrimination+analysis+(pls-da)/partial+least+squares+discriminant+analysis++pls+da+/pm40246482-88-5-26
    Average 90 stars, based on 1 article reviews
    partial least squares discriminant analysis (pls-da) - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    MathWorks Inc partial least squares discriminant analysis (pls-da)
    Multivariate analysis of urinary ¹H NMR metabolomic profiles across groups: Primary Mitochondrial Disease (PMD, orange), Suspected Mitochondrial Disease (SMD, yellow), Control individuals (green), Chronic Kidney Disease (CKD) stages 1–2 (lilac) and stages 3–5 (purple). The ellipses represent 95% confidence intervals. A Principal Component Analysis (PCA) highlights distinct metabolic fingerprint in CKD patients compared to other groups. B Corresponding supervised model using <t>partial</t> <t>least</t> <t>squares</t> discriminant analysis <t>(PLS-DA)</t> shows metabolic divergence between groups, particularly between PMD, CKD3-5, and controls. PMD primary mitochondrial disease, SMD suspected mitochondrial dysfunction, CKD chronic kidney disease
    Partial Least Squares Discriminant Analysis (Pls Da), supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/partial+least-squares+discrimination+analysis+(pls-da)/pm40186885-135-2-11
    Average 90 stars, based on 1 article reviews
    partial least squares discriminant analysis (pls-da) - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    Image Search Results


    Multivariate analysis of urinary ¹H NMR metabolomic profiles across groups: Primary Mitochondrial Disease (PMD, orange), Suspected Mitochondrial Disease (SMD, yellow), Control individuals (green), Chronic Kidney Disease (CKD) stages 1–2 (lilac) and stages 3–5 (purple). The ellipses represent 95% confidence intervals. A Principal Component Analysis (PCA) highlights distinct metabolic fingerprint in CKD patients compared to other groups. B Corresponding supervised model using partial least squares discriminant analysis (PLS-DA) shows metabolic divergence between groups, particularly between PMD, CKD3-5, and controls. PMD primary mitochondrial disease, SMD suspected mitochondrial dysfunction, CKD chronic kidney disease

    Journal: Metabolomics

    Article Title: NMR-based urinary biomarkers in pediatric primary mitochondrial disorders and chronic kidney disease: shared mitochondrial dysfunction, diverging biosignatures

    doi: 10.1007/s11306-025-02363-8

    Figure Lengend Snippet: Multivariate analysis of urinary ¹H NMR metabolomic profiles across groups: Primary Mitochondrial Disease (PMD, orange), Suspected Mitochondrial Disease (SMD, yellow), Control individuals (green), Chronic Kidney Disease (CKD) stages 1–2 (lilac) and stages 3–5 (purple). The ellipses represent 95% confidence intervals. A Principal Component Analysis (PCA) highlights distinct metabolic fingerprint in CKD patients compared to other groups. B Corresponding supervised model using partial least squares discriminant analysis (PLS-DA) shows metabolic divergence between groups, particularly between PMD, CKD3-5, and controls. PMD primary mitochondrial disease, SMD suspected mitochondrial dysfunction, CKD chronic kidney disease

    Article Snippet: Multivariate analysis (MVA) trough Principal component analysis (PCA) and partial-least-squares discriminant analysis (PLS-DA) models (SIMCA-P 11.5, Umetrics, Umeå, Sweden), were performed on full resolution 1 H NMR spectra, after unit variance (UV) scaling of the spectra.

    Techniques: Metabolomic, Control

    Supervised multivariate models and spectral features associated with mitochondrial disorders. I. Partial Least Squares Discriminant Analysis (PLS-DA) models were generated to compare patients with PMD to: A controls, B SMD, C . CKD stages 1–2, and D . CKD stages 3–5. The corresponding Q² values, indicate the predictive performance of each model. Clear discrimination was observed between PMD and controls (Q² = 0.53), and both CKD subgroups (Q² = 0.62 and 0.78). In contrast, the model comparing PMD to SMD showed lower predictive performance (Q² = 0.25), reflecting significant metabolic overlap. II. Corresponding loadings plot of model A, color-coded by variable importance in projection (VIP) scores for the first latent variable (LV1) highlighting spectral regions that contribute most to the separation between PMD and controls. (regions around 1.2–2.5 ppm and 3.0–4.5 ppm, consistent with metabolites involved in amino acid metabolism, organic acids, and energy-related pathways). Three-letter code used for amino acids. Abbreviations: 3-HBA: 3-hydroxybutyrate; 4-HPA: 4-hydroxyphenylacetate; N -PhAcGly: N -phenylacetylglycine. Ui: resonances at chemical shift i, which remain unassigned (or with tentative assignment)

    Journal: Metabolomics

    Article Title: NMR-based urinary biomarkers in pediatric primary mitochondrial disorders and chronic kidney disease: shared mitochondrial dysfunction, diverging biosignatures

    doi: 10.1007/s11306-025-02363-8

    Figure Lengend Snippet: Supervised multivariate models and spectral features associated with mitochondrial disorders. I. Partial Least Squares Discriminant Analysis (PLS-DA) models were generated to compare patients with PMD to: A controls, B SMD, C . CKD stages 1–2, and D . CKD stages 3–5. The corresponding Q² values, indicate the predictive performance of each model. Clear discrimination was observed between PMD and controls (Q² = 0.53), and both CKD subgroups (Q² = 0.62 and 0.78). In contrast, the model comparing PMD to SMD showed lower predictive performance (Q² = 0.25), reflecting significant metabolic overlap. II. Corresponding loadings plot of model A, color-coded by variable importance in projection (VIP) scores for the first latent variable (LV1) highlighting spectral regions that contribute most to the separation between PMD and controls. (regions around 1.2–2.5 ppm and 3.0–4.5 ppm, consistent with metabolites involved in amino acid metabolism, organic acids, and energy-related pathways). Three-letter code used for amino acids. Abbreviations: 3-HBA: 3-hydroxybutyrate; 4-HPA: 4-hydroxyphenylacetate; N -PhAcGly: N -phenylacetylglycine. Ui: resonances at chemical shift i, which remain unassigned (or with tentative assignment)

    Article Snippet: Multivariate analysis (MVA) trough Principal component analysis (PCA) and partial-least-squares discriminant analysis (PLS-DA) models (SIMCA-P 11.5, Umetrics, Umeå, Sweden), were performed on full resolution 1 H NMR spectra, after unit variance (UV) scaling of the spectra.

    Techniques: Generated